P. Duic

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.

John A Butman, Paul S Albert, Kevin Camphausen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

Steven R. Abram, T. Mikkelsen, S. Toms, 2018, Journal of Translational Medicine.

In-111 DTPA ommaya cisternography with delayed radiotracer activity demonstrated in the peritoneal cavity.

D. Katz, L. R. Scalcione, E. Yung, 2009, Clinical nuclear medicine.

A Phase I Trial of Enzastaurin in Patients with Recurrent Gliomas

J. Walling, H. Fine, P. Albert, 2009, Clinical Cancer Research.

Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

Steven R. Abram, T. Mikkelsen, S. Toms, 2018, Journal of Translational Medicine.

Time interval from diagnosis to treatment of brain metastases with stereotactic radiosurgery is not associated with radionecrosis or local failure

M. Akerman, J. Lischalk, T. Carpenter, 2023, Frontiers in Oncology.

Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma

N. Mohile, L. Nabors, S. Hsu, 2024, Neuro-oncology advances.